J Biol Chem, Vol. 275, Issue 19, 14708-14716, May 12, 2000
Successive Expression and Activation of NFAT Family Members
during Thymocyte Differentiation*
Satoko
Adachi
,
Yoshiharu
Amasaki§,
Shoichiro
Miyatake§,
Naoko
Arai¶, and
Makoto
Iwata
From the
Integrative Projects, Mitsubishi Kasei
Institute of Life Sciences, Machida-shi, Tokyo 194-8511, Japan,
§ Department of Molecular and Developmental Biology,
Institute of Medical Sciences, The University of Tokyo, CREST,
Minato-ku, Tokyo 108-0071, Japan, and ¶ Department of Immunology,
DNAX Research Institute of Molecular and Cellular Biology,
Palo Alto, California, 94304-1104
 |
ABSTRACT |
Differentiation of immature
CD4+CD8+ thymocytes to mature
CD4+ or CD8+ T cells is induced by positive
selection and appears to involve calcineurin-dependent
activation of NFAT, a family of transcription factors. NFATx is
predominantly expressed in CD4+CD8+ thymocytes,
whereas NFATp and NFATc are expressed at much lower levels in the
thymus than in mature T cells. However, how or when each NFAT member is
involved in the differentiation pathway is unclear. Using an in
vitro model system where isolated
CD4+CD8+ thymocytes can survive and
differentiate into semi-mature CD4-lineage T cells, we suggest that low
calcineurin activity sustained for approximately 20 h is required
for cell survival and differentiation. Accordingly, the DNA binding
activity of NFAT slowly increased during the stimulation of 20 h
to induce the differentiation. NFATx significantly contributed to the
early rise, but the late increase was mostly due to NFATc activation.
Meanwhile, the expression of NFATx mRNA decreased and that of NFATc
mRNA increased. The DNA-binding activity of NFATp was detectable
but low throughout the stimulation. NFATp became dominantly active
after the semi-mature T cells differentiated into mature and activated
CD4 T cells. These findings suggest that NFATx and NFATc successively
play roles in T cell development.
 |
INTRODUCTION |
Clonal selection of immature T cells occurs at the
CD4+CD8+ stage in the thymus. Useful clones are
rescued from apoptosis and differentiate into mature
CD4+CD8
or CD4
CD8+
single-positive (SP)1 cells
by positive selection (1). Positive selection is considered to be based
on weak interactions between T cell receptors (TCR) and major
histocompatibility complex-encoded molecules and to require proper
levels of signals through TCR/CD3 and accessory molecules such as
LFA-1, CD4, and CD8 (2-4). Signaling molecules including ZAP-70, Vav,
p21ras, c-Raf, classical Ca2+-dependent
protein kinase C, and calcineurin (CN) are suggested to be involved in
this event (5-11). CN activation is dependent on Ca2+
mobilization. The active CN dephosphorylates the transcription factor
NFAT that resides in the cytoplasm and accelerates its translocation to
the nucleus. Among the four members of the NFAT family, NFATp (NFAT1 or
NFATc2), NFATc (NFAT2 or NFATc1), and NFATx (NFAT4 or NFATc3) are
expressed in lymphoid organs, whereas NFAT3 (NFATc4) is expressed in
nonlymphoid organs (12-15). NFATp is constitutively expressed in
mature T cells. NFATc is expressed in thymus and peripheral lymphoid
organs at low levels, and its transcripts are markedly increased in
mature T cells upon activation through the TCR complex (13). NFATx is
predominantly expressed in CD4+CD8+ thymocytes
(16). In NFATx-deficient mice, the number of SP thymocytes is about
half that of normal mice, and their CD4+CD8+
thymocytes are more sensitive to glucocorticoid-induced apoptosis than
normal CD4+CD8+ thymocytes (16).
NFATc-deficient mice have cardiac valvular defects and are
embryonic-lethal. Thus, by using RAG-deficient blastocyst
complementation, it was shown that young chimeric mice lacking NFATc
have reduced numbers of thymocytes (17, 18). On the other hand, NFATp
deficiency does not cause any significant alteration in thymocyte
differentiation (19, 20). Thus, positive selection may involve NFATx
and NFATc activation and induce succession of NFAT family members. It
is not known, however, when or how the activation and succession of
NFAT family members occurs during positive selection. To resolve this
issue, it is necessary to perform quantitative and kinetic analysis of
positive selection in the absence of other cell types such as thymic
epithelial cells.
We have established an in vitro model system for positive
selection in which isolated CD4+CD8+ thymocytes
survive and differentiate into semi-mature T cells committed to the
CD4- or CD8-T cell lineage by using defined combinations of the calcium
ionophore ionomycin (IM) and the protein kinase C activator PMA
(21-23). The combinations of drugs were originally chosen to mimic the
anti-apoptotic effect of proper cross-linking of TCR/CD3 and CD4, CD8,
or LFA-1 on thymocytes (10, 24, 25). Combinations of IM and PMA are
known to mimic antigenic stimulation in mature T cells. However, the
concentration ranges required for thymocyte survival and
differentiation are narrower and lower than those that induce
proliferation of mature T cells (26), indicating that the stimulation
intensities for differentiation have to be relatively low and within a
narrow range.
The duration as well as intensity of stimulation are crucial for
differentiation (21-23). In the present study, we found that FK506
affected thymocyte differentiation even when it was added to the
culture at the late stage of the stimulation. Thus, sustained activities of CN and NFAT are likely to be required for the
differentiation. From the semi-mature T cells that are committed to the
CD4-T cell lineage in vitro, mature and activated CD4 SP T
cells are induced by secondary-pulse stimulation with a combination of
IM and PMA followed by incubation with IL-2 (22). By using the in
vitro system, we analyzed kinetic changes in the expression and
activation of NFAT family members during the differentiation of
isolated CD4+CD8+ thymocytes into mature CD4 T
cells. Although it has been difficult to induce and detect the NFAT DNA
binding activity in murine CD4+CD8+ thymocytes,
we could detect the activities and observe the succession of expression
and DNA binding activities of NFAT family members in these cells. These
changes in NFAT members were induced by a limited number of defined
stimuli without thymic microenvironments or other cell types,
suggesting that the changes may be intrinsically programmed along with
T cell development.
 |
EXPERIMENTAL PROCEDURES |
Mice--
BOG8 TCR
transgenic mice were generated as
described previously (21). The TCR
is specific for an
ovalbumin-derived peptide (P271-285) and is restricted to
I-Ad. The mice of RAG-2(
/
) background were generated by
breeding at least twice with RAG-2 knockout 129 mice
(H-2bv1) (27). In these mice with H-2b and/or
H-2bv1 backgrounds, essentially all thymocytes were
CD4+CD8+ cells and almost no peripheral T cells
were found at least until 8 weeks of age, suggesting that positive
selection did not occur. BALB/c mice (4 to 8 weeks of age) were
obtained from Japan SLC (Shizuoka, Japan).
Cell Culture--
Thymocytes were obtained from the TCR
transgenic mice or normal BALB/c mice. Normal
CD4+CD8+ thymocytes were purified from BALB/c
thymocytes with peanut agglutinin as described previously (10).
Thymocytes (3.75 to 4 × 106) were suspended in 1 ml
Dulbecco's modified Eagle's medium supplemented with 10%
heat-inactivated fetal calf serum (Intergen, Purchase, NY), 3 mM L-glutamine, 1 mM sodium
pyruvate, 1× minimum Eagle's medium non-essential amino acids, 50 µM 2-mercaptoethanol, 20 mM HEPES (pH 7.2), 20 units of
penicillin, and 20 µg of streptomycin (complete Dulbecco's modified
Eagle's medium) and were cultured for the indicated time at 37 °C
in the presence or absence of the indicated concentrations of IM
(Calbiochem) and PMA (Sigma) in 24-well tissue culture plates (Corning
25820, Corning, NY). Each lot of fetal calf serum was selected by its
low toxicity to CD4+CD8+ thymocytes. In some
experiments, cells were washed twice with fresh medium after culturing
and were further cultured in complete Dulbecco's modified Eagle's
medium. Viable cells were enumerated by trypan blue dye exclusion. The
recovery (%) of viable cells was calculated as (E/S) × 100, where E and S stand for viable cell number at the end of culture and
that at the start of culture, respectively. For the secondary
stimulation, cells were cultured with 0.2 µg/ml IM and 3 ng/ml PMA
for 17 h, washed, and incubated further with 50 units/ml mouse
rIL-2 (Genzyme, Cambridge, MA) for 48 h. In some experiments, 1 nM FK506 (Calbiochem) or 1 nM rapamycin
(Calbiochem) was included in the culture.
Co-receptor Re-expression Assay--
The cells were treated with
Pronase to strip off CD4 and CD8, cultured for 24 h, and then
assessed for CD4/CD8 expression as described (21, 28).
Flow Cytometric Analysis and Sorting--
For two-color flow
cytometric analysis of CD4 and CD8 expression, the cells were stained
with labeled Abs; phycoerythrin-conjugated anti-CD4 mAb (RM4-5) and
fluorescein isothiocyanate-labeled mAb to CD8 (53-6.7) (Pharmingen).
Viable cells were gated by forward and side scattering with a FACScan
flow cytometer and FACScan Research Software (Becton Dickinson, Lincoln
Park, NJ), and were analyzed for co-receptor expression. The gate for
viable cells was determined by using propidium iodide exclusion and
Paint-a-Gate software (Becton Dickinson). For sorting of
CD69+ and CD69
subsets, thymocytes from
BALB/c mice were stained with fluorescein isothiocyanate-labeled mAb to
CD69 (H1.2F3) (Pharmingen). Viable cells were gated by forward and side
scattering and were sorted into CD69+ and
CD69
subpopulations with FACStar plus and Consort 30 software programs (Becton Dickinson).
Preparation of Nuclear Extract--
To analyze NFAT DNA binding
activity, nuclear extracts were prepared from thymocytes as described
previously (29), with modifications. Briefly, 1 to 2 × 108 cells were washed with cold phosphate-buffered saline
and resuspended in buffer A (10 mM HEPES, pH 7.6, 15 mM KCl, 2 mM MgCl2, and 0.1 mM EDTA). The suspension was mixed with an equal volume of
buffer B (buffer A plus 0.1% Nonidet P-40), and the resulting nuclei were pelleted by brief, low speed centrifugation. The nuclear pellet
was washed with buffer A, resuspended in 200 µl of buffer C (50 mM HEPES, pH 7.9, 50 mM KCl, 0.1 mM
EDTA, and 10% glycerol) containing 0.3 M ammonium sulfate
(pH 7.9) and vortexed vigorously for 30 min at 4 °C. The nuclear
debris was pelleted by high speed centrifugation at 220,000 × g for 45 min. Then the proteins in the supernatant were
precipitated by adding an equal volume of 3.0 M ammonium
sulfate (pH 7.9). The suspension was incubated on ice for 2 to 3 h
and centrifuged at 110,000 × g for 15 min. The nuclear
proteins in the pellet were dissolved in 20 µl of buffer C by
vortexing for 30 min at 4 °C and stored at
80 °C until use. All
buffers were supplemented with 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10 µM
pepstatin A, and 4 µM leupeptin. Protein concentration
was estimated by BCA protein assay kit (Pierce). To analyze AP-1 DNA
binding activity, nuclear extracts were prepared by the method
described by Schreiber et al. (30).
Anti-NFAT Abs--
A StuI/BalI 426-bp
fragment of mouse NFATx cDNA (corresponding to amino acid residues
331-462 of the mouse NFATx protein (31)) was subcloned into pGEX-5X-3
vector (Amersham Pharmacia Biotech), and truncated mouse NFATx protein
fused to glutathione S-transferase was bacterially
expressed. The resulting recombinant protein was purified and used for
immunizing rabbits to raise an anti-mouse NFATx anti-serum (termed
DN97). The anti-murine NFATc mAb and the anti-murine NFATp antiserum
were purchased from Affinity Bioreagents (Golden, CO) and Upstate
Biotechnology Corp. (Lake Placid, NY), respectively.
Plasmid Construction and Expression of NFAT
Proteins--
pME-mNFATx1 and pME-mNFATc are expression plasmids
containing mouse NFATx and NFATc full-length cDNA under the control
of the SR
promoter in the pME18S mammalian expression vector (31, 32). pME-mNFAT1C expression plasmid was generated by subcloning an
EcoRI/HindIII fragment from pGLP3-mNFAT1C (33) (a
generous gift from Dr. A. Rao) encoding full-length mouse NFAT1C
cDNA into the pME18S vector cleaved by
EcoRI/SpeI. Transfection of plasmids into COS-7
cells by the DEAE-dextran method and the subsequent preparation of
cytosolic extracts were carried out as described previously (29,
34).
EMSA--
NFAT-DNA binding reactions were performed by
incubating 5 to 10 µg of nuclear extracts with 0.05 pmol of a
radiolabeled double-stranded oligonucleotide probe for 20 min at room
temperature in 15 µl of the binding buffer (10 mM HEPES
(pH 7.9), 100 mM KCl, 1 mM EDTA, 10% glycerol)
containing 0.75 µg of poly(dI-dC) (Amersham Pharmacia Biotech). Cold
oligonucleotide competitors (5 pmol) were added to the reaction mixture
when indicated. For supershift assays, an anti-NFAT Ab was added to the
reaction mixture followed by an additional 20 min of incubation at room
temperature. The protein-DNA complexes were separated by
electrophoresis on a nondenaturing 4% polyacrylamide gel with a 0.25×
Tris borate EDTA buffer at 120 V for 1.5 h at room temperature.
AP-1-DNA binding reactions were performed by a Trevigen gel shift kit
(Trevigen; Gaithersburg, MD), and the protein-DNA complexes were
analyzed according to the kit instructions. The double-stranded
oligonucleotides used in this study were as follows: the distal NFAT
site from the human IL-2 promoter for NFAT binding,
5'-gatcGGAGGAAAAACTGTTTCATACAGAAGGCGT-3' (sequence of overhang is
lowercase); the AP-1 consensus sequence oligonucleotides (Trevigen) for
AP-1 binding, 5'-CGCTTGATGAGTCAGCCGGAA-3'. The former
oligonucleotide was labeled with [
-32P]dATP by filling
the 5' overhang with Klenow fragments, and the latter was labeled by
phosphorylation with [
-32P]ATP and T4 polynucleotide kinase.
Semi-quantitative RT-PCR--
Total RNA was prepared from
thymocytes cultured for the indicated time by using the lysis buffer
Isogen (Wako Pure Chemical, Tokyo, Japan). Oligo-dT-primed first strand
cDNA was prepared from 5 µg of total RNA using the Superscript II
reverse transcriptase (Life Technologies, Inc.), and the resulting
cDNA was serially diluted. PCR was performed in a total volume of
27 µl containing 0.5 µl of appropriately diluted cDNA, 0.15 mM dNTP, 1 µM each primer, and 1× PCR buffer
(Roche Molecular Biochemicals), and 0.5 units of AmpliTaq DNA
polymerase (Roche Molecular Biochemicals) by using a Takara PCR thermal
cycler (TP480). AmpliTaq DNA polymerase was added during the first
denaturation step (94 °C for 3 min). The amplification was then
performed by 25-39 cycles of 94 °C for 30 s, 57 °C for
30 s, and 72 °C for 1 min (25 cycles for
-actin, 32 cycles
for NFATx and NFATc, 39 cycles for NFATp). The final cycle was followed
by an extension step of 3 min at 72 °C. Sequences of the
sense and antisense primers were as follows:
-actin,
5'-CGTGGGCCGCCCTAGGCACCA-3' and 5'-TTGGCCTTAGGGTTCAGGGGGG-3' (35);
NFATx, 5'-CTTTCAGTTCCTTCACCCTTTACCT-3' and
5'-TGCCAATATCAGTTTCTCCTTTTC-3'; NFATc, 5'-CAACGCCCTGACCACCGATAG-3' and
5'-GGCTGCCTTCCGTCTCATAGT-3'; NFATp, 5'-GGGCCATGTGAGCAGGAGGAGA-3' and
5'-GCGTTTCGGAGCTTCAGGATGC-3'. PCR products were resolved by electrophoresis on a 1.2% agarose gel containing ethidium bromide. NFATx, NFATc, NFATp, and
-actin cDNA yielded PCR products of 499 bp, 392 bp, 515 bp, and 243 bp, respectively. Fluorescence images were
captured by a video monitor system (ATTO Image Freezer, ATTO, Tokyo,
Japan), and band intensities were quantified using the analytical
program Densitograph 4.0 (ATTO). The bands that were corresponded to
the exponential amplification phases were analyzed, and the intensities
of NFAT cDNA-derived bands were normalized with those of
-actin
cDNA-derived bands.
 |
RESULTS |
Duration as Well as Intensity of the Ca2+ Signal Is
Crucial for the Differentiation of CD4+CD8+
Thymocytes--
To obtain CD4+CD8+ thymocytes
free from mature CD4 or CD8 SP T cells, we used BOG8 TCR transgenic
mice with nonselecting major histocompatibility complex and
RAG-2(
/
) backgrounds. The T cell differentiation in these mice is
arrested at the CD4+CD8+ stage without positive
selection, and essentially all thymocytes are
CD4+CD8+ (Fig.
1A) (21, 22). According to our
in vitro model system for thymocyte positive selection, the
isolated CD4+CD8+ thymocytes were stimulated
with a defined combination of IM and PMA (0.2 µg/ml and 0.2 ng/ml,
respectively) for 20 h, washed, and further cultured for 24 h
without drugs (21). The resultant cells were semi-mature CD4 SP or
CD4+CD8low T cells (Fig. 1F). The
lineage commitment was assessed by the co-receptor re-expression assay
(28). The cultured thymocytes were treated with Pronase to remove the
surface CD4/CD8 co-receptors and were cultured overnight without
stimulation to let the cells re-express the co-receptor they actively
produce. Twenty hours of stimulation with IM/PMA resulted in the
optimal induction of the CD4-lineage committed cells (Fig.
1K), whereas 15 h of stimulation resulted in the
induction of CD8-lineage committed cells and some CD4-lineage committed
cells (Fig. 1J). When the stimulation period was shorter
than 15 h, none or a lesser proportion of the cells differentiated
into the CD4 lineage. IM/PMA stimulation for longer than 20 h
resulted in a significant loss of viable cells and the induction of
CD4
CD8
cells (data not shown) (22). These
results suggest that the incubation period as well as the drug
concentrations were crucial for the induction of
CD4+CD8+ thymocyte differentiation.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 1.
Duration of stimulation with the combination
of IM/PMA is crucial for the differentiation of
CD4+CD8+ thymocytes in
vitro. CD4+CD8+ thymocytes
(A) from BOG8 TCR transgenic mice with nonselecting major
histocompatibility complex and RAG-2( / ) backgrounds were cultured
with 0.2 µg/ml IM and 0.2 ng/ml PMA for 0 h (B),
2 h (C), 8 h (D), 15 h
(E), or 20 h (F) and then washed and
cultured in the absence of drugs for 44, 42, 36, 29, or 24 h,
respectively (total of 44 h). The recovery of viable cells was
46.1% (B), 52.5% (C), 39.7% (D),
66.7% (E), and 80.4% (F), respectively. The
cells from B, C, D, E, and
F were treated with Pronase, washed, and cultured for
18 h (G, H, I, J, and
K, respectively). CD4 and CD8 expression was analyzed. A
representative result of three experiments is shown. DP,
double-positive.
|
|
The addition of FK506, but not rapamycin, at the beginning of the
culture inhibited differentiation of the cells and induced apoptosis
(Fig. 2 and data not shown). FK506 is an
immunosuppressant that inhibits CN activation through binding to
FKBP12, whereas rapamycin is another immunosuppressant that binds to
FKBP12 without affecting CN activity (36). FK506 was moderately
effective when it was added 15 h after the start of culture with
IM/PMA (Fig. 2, D and G) but did not affect
differentiation or survival when it was added after the stimulation
period (data not shown). These findings suggest that sustained CN
activity is required for differentiation.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of delayed addition of FK506 on the
IM/PMA-induced differentiation of CD4+CD8+
thymocytes. CD4+CD8+ thymocytes from the
transgenic mice were cultured with the combination of 0.2 µg/ml IM
and 0.2 ng/ml PMA for 20 h and further cultured for 24 h in
the absence of IM/PMA. FK506 (1 nM) was added to each well
at 0 h (A), 2 h (B), 8 h
(C), or 15 h (D) after the start of
culturing with IM/PMA. FK506 was not added to control culture
(E). The recovery of viable cells was 7.8% (A),
5.9% (B), 31.5% (C), 58.9% (D), and
80.4% (E), respectively. The recovery from A and
B was too low to perform co-receptor re-expression assay.
The cells from C, D, and E were
treated with Pronase, washed, and cultured for 18 h for
co-receptor re-expression (F, G, and
H, respectively). CD4 and CD8 expression was analyzed. A
representative result of three experiments is shown. ND, not
determined. DP, double-positive.
|
|
Kinetic Changes in the DNA Binding Activities of NFAT Family
Members in T Cells during Differentiation of
CD4+CD8+ Thymocytes to CD4 SP T Cells in
Vitro--
Since it is known that the activation of CN in T cells is
precisely followed by the activation of its major target NFAT, we analyzed NFAT activation during thymocyte differentiation induced by
the transient stimulation with IM and PMA in vitro. DNA
binding activity of NFAT was detected by EMSA in the nuclear extract of cells that had been stimulated for 2 h with IM/PMA (Fig.
3A). The NFAT DNA binding
activity was increased thereafter and reached a maximum within 15 h of stimulation. Multiple bands were detected during the stimulation,
but most of them became undetectable in the presence of an excess
amount of cold DNA probe with an NFAT-binding site (Fig.
3B). Thus, there may be multiple forms of NFAT-DNA complexes. After removing IM/PMA from the culture, the NFAT-DNA complexes quickly disappeared (Fig. 3A).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 3.
Kinetic analysis of DNA binding activity of
NFAT during the differentiation of CD4+CD8+
thymocytes into CD4-lineage committed cells.
CD4+CD8+ thymocytes from the transgenic mice
were cultured with the combination of 0.2 µg/ml IM and 0.2 ng/ml PMA
for 20 h and further cultured for 24 h in the absence of
IM/PMA. Aliquots of the cells were recovered at the indicated time.
A, nuclear extracts were obtained from the cells cultured
for the indicated period and were assessed for DNA binding activity of
NFAT by EMSA with the oligonucleotide containing the human IL-2
promoter distal NFAT site (lanes 1-6). B,
nuclear extracts were obtained from the cells cultured for 20 h
with IM/PMA, and NFAT DNA binding activity in the extracts was analyzed
in the presence or absence of a 100-fold excess amount of cold DNA
probe (lanes 7 and 8). A representative result of
three experiments is shown.
|
|
To analyze the contribution of each NFAT family member, the super shift
assay was performed with specific Abs. The Abs to NFATc and NFATp were
commercially available, but the Ab to mouse NFATx was produced as
described under "Experimental Procedures." Its specificity was
confirmed by using COS-7 cells expressing mouse NFAT members (Fig.
4). The DNA binding activity of NFATx was
detected in the nuclear extract of cells stimulated for 2 h with
IM/PMA, but it decreased after 15 h of stimulation (Fig. 5, lanes 2 and 6).
These supershift bands were specific for NFATx-DNA complexes, since
neither control Abs with the nuclear extract nor the anti-mouse NFATx
anti-serum without the nuclear extract induced a similar band (data not
shown). However, the intensity of the main band of NFAT-DNA complexes
without Abs was rather enhanced in the presence of the anti-mouse NFATx
anti-serum in some experiments (Fig. 5, lanes 1 and
2). It was partly due to a nonspecific effect of the
anti-serum, since the anti-serum alone induced a nonspecific band at
almost the same position (data not shown). The addition of the
anti-NFATp antiserum supershifted the NFATp-DNA complex (Fig. 5,
lanes 4 and 8). The intensities of the supershift
bands indicated that the DNA binding activity of NFATp was induced
after 2 h of stimulation with IM/PMA and was almost unchanged
after 15 h of stimulation. The anti-NFATc mAb also supershifted
NFATc-DNA complex (Fig. 5, lanes 3 and 7), although the retardation of the mobility was less than in the case of
the anti-NFATx and anti-NFATp antisera. This may be partly because the
anti-NFATc mAb recognizes a single epitope on NFATc, and the predicted
molecular size of NFATc is smaller than that of NFATx or NFATp (29).
The intensities of the supershift bands indicated that the DNA binding
activity of NFATc was induced after 2 h of stimulation with IM/PMA
and was dramatically increased over 15 h of stimulation.

View larger version (115K):
[in this window]
[in a new window]
|
Fig. 4.
Specific reactivity of the anti-mouse NFATx
Ab. EMSA was performed by using cytosolic extracts from COS-7
cells transfected with empty vector (pME18S, lanes 1 and
2) or expression plasmids for mouse NFATx (pME-mNFATx1,
lanes 3-5), mouse NFATc (pME-mNFATc, lanes
6-8), and mouse NFATp (pME-mNFAT1C, lanes 9-11).
Where indicated (lanes 2-11), nuclear extract from
PMA-stimulated HeLa cells, as a source of exogenous AP-1 protein, was
included in the binding mixture with 1 ng of the NFAT oligonucleotide
probe (30). The specificity of COS-expressed NFAT proteins for binding
DNA has been shown elsewhere (32, 33). A saturating amount of the
anti-NFATx anti-serum (DN97, 0.5 ml) was predetermined. Specificity of
anti-NFATc and anti-NFATp Abs were similarly evaluated elsewhere (30).
NRS, nonimmunized rabbit serum as a control.
|
|

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 5.
DNA binding activities of NFAT family
members, NFATx, NFATc, and NFATp are detected in nuclear extracts from
the cells stimulated with IM/PMA for 2 or 15 h.
CD4+CD8+ thymocytes from the TCR transgenic
mice were stimulated with the combination of 0.2 µg/ml IM and 0.2 ng/ml PMA for 2 (lanes 1-4) or 15 h (lanes
5-8). The NFAT-DNA complexes in nuclear extracts from the cells
were characterized with specific Abs against NFATx, NFATc, and NFATp. A
representative result of three experiments is shown.
|
|
Co-operation of NFAT and AP-1 (Fos/Jun) or AP-1-related factors is
thought to be required for the maximal NFAT transcription activity in
NFAT/AP-1-binding sites including the distal NFAT site of the human
IL-2 promoter (37). PMA may induce the de novo synthesis and
post-translational modification of AP-1 and other transcription factors
(37). Since IM or PMA alone fails to induce differentiation of
CD4+CD8+ thymocytes (21, 37), the
differentiation of CD4+CD8+ thymocytes might
also require activation of both NFAT and AP-1. Indeed, the NFAT-DNA
complexes included in CD4+CD8+ thymocytes in
the current study were also likely to contain AP-1-like factors, since
these complexes were quenched by excess amounts of cold AP-1
oligonucleotide (data not shown). Although controversial results have
been reported on the DNA binding activity of AP-1 in IM/PMA-stimulated
CD4+CD8+ thymocytes in vitro
(39-41), we detected a time-dependent increase in AP-1 DNA
binding activity in the cultured thymocytes of BOG8 TCR transgenic mice
upon stimulation with 0.2 µg/ml IM and 0.2 ng/ml PMA (data not shown).
The semi-mature T cells differentiated from
CD4+CD8+ thymocytes were re-stimulated with a
combination of IM and PMA for 17 h, washed, and cultured with
mouse rIL-2 for 48 h. The resultant cells consisted of CD4 SP and
some CD4
CD8
cells and had the phenotypes of
mature and activated T cells as described previously (22). Recently,
IL-2 stimulation of T cells has been shown to induce NFAT DNA binding
activity (42). The DNA binding activity of NFAT was detected by EMSA as
2 bands (Fig. 6, lane 1).
These bands disappeared in the presence of an excess amount of cold DNA
probe with an NFAT-binding site, but only the upper band disappeared in
the presence of an excess amount of cold DNA probe with an AP-1-binding
site (data not shown), indicating that the upper band, but not the
lower one, contains AP-1 or AP-1-related factors in the complex. The
DNA-binding activity of NFAT was dominated by that of NFATp in these
cells (Fig. 6, lane 4). These findings collectively suggest
that NFATx and NFATc differentially contribute to the sequential
processes of thymocyte positive selection and that NFATp up-regulation
accompanies T cell maturation.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
NFATp is dominantly responsible for the NFAT
DNA binding activity in the mature and activated CD4 SP T cells
differentiated from CD4+CD8+ thymocytes
in vitro. The CD4-lineage committed cells were
induced from CD4+CD8+ thymocytes as described
in Fig. 3 and were restimulated for 17 h with 0.2 µg/ml IM and
3.0 ng/ml PMA. After removing the drugs, these cells were further
cultured for 48 h with 50 units/ml of mouse rIL-2. DNA binding
activity of NFAT was assessed by EMSA (lane 1) as described
in Fig. 3. The NFAT-DNA complexes were characterized by super shift
assay (lanes 2 to 4) with Abs to NFAT family
members as described in Fig. 5. A similar result was obtained by
another independent experiment.
|
|
Kinetic Changes in the Expression of NFAT Family Genes in T Cells
during the Differentiation of CD4+CD8+
Thymocytes to CD4 SP T Cells in Vitro--
To examine whether the
expression of NFAT genes alters along with the differentiation of
thymocytes in vitro, we analyzed the mRNA levels of NFAT
members during culturing. mRNA was obtained from aliquots of cells
harvested before and after 2 or15 h of stimulation with IM/PMA and from
those harvested after maturation. The expression levels of NFATx,
NFATc, and NFATp genes were assessed by semi-quantitative RT-PCR. As
shown in Fig. 7, during the first stimulation, the expression of NFATx mRNA decreased quickly,
whereas that of NFATc mRNA significantly increased. The expression
of NFATp mRNA increased after 15 h of stimulation. After
maturation of the cells, the mRNA expression of NFATc dramatically
decreased corresponding to the removal of drugs. The mRNA levels of
NFATp remained high at the final stage. Thus, succession of NFAT
members indeed occurred during the differentiation and maturation of
CD4+CD8+ thymocytes in vitro.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 7.
mRNA expression levels of NFAT members
changed during the differentiation of CD4+CD8+
thymocytes into mature CD4 SP T cells in vitro.
Differentiation of CD4+CD8+ thymocytes to
mature and activated CD4 SP T cells was induced as described in Fig. 6.
An aliquot of the cells was recovered from the culture at the indicated
time, and mRNA expression in the cells was assessed by
semi-quantitative RT-PCR. A, the reverse transcribed
cDNA from thymocytes stimulated with IM/PMA for 0, 2, and 15 h
and that from mature and activated CD4 SP T cells were serially
diluted, and each diluted sample was subjected to PCR amplification for
NFATx, NFATc for 32 cycles, NFATp for 39 cycles, and -actin for 25 cycles. The PCR products were resolved by electrophoresis on a 1.2%
agarose gel containing ethidium bromide. B, the bands
corresponded to the exponential amplification phase were analyzed, and
the intensities of NFAT cDNA-derived bands were normalized with
those of -actin cDNA-derived bands. Relative expression levels
of mRNA of each NFAT member were calculated. A representative
result of three experiments is shown.
|
|
Physiological Changes in the Expression of NFAT Family Genes in
Normal Thymocytes during Positive Selection--
It is known that CD69
is transiently expressed in the cells undergoing positive selection or
the cells that had been selected recently in the thymus (43, 44).
Accordingly, during the differentiation of
CD4+CD8+ thymocytes in vitro, CD69
expression gradually increased and reached the maximum level after
15 h of stimulation and gradually decreased after removing IM/PMA
from the culture medium (Fig. 8A). To test if the succession
of NFAT members observed in vitro is in accord with
physiological changes in the expression of NFAT family genes, we
analyzed expression levels of these genes in CD69+ and
CD69
subsets of normal thymocytes. In general, the
majority of CD69
cells are
CD4+CD8+ thymocytes at the pre-selection stage
(roughly about 90%); the rest of CD69
cells are mainly
at the post-selection stage (44). As shown in Fig. 8, C and
D, the expression level of NFATx mRNA in
CD69+ cells was lower than that in CD69
cells. In contrast, the expression levels of NFATc and NFATp mRNA
in CD69+ cells was higher than those in CD69
cells. The results indicate that the changes in mRNA expression of
NFAT members during normal thymic differentiation are paralleled by the
changes in the in vitro culture system.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 8.
Thymocyte positive selection in
vivo is also accompanied by a decrease in the expression of
NFATx mRNA and increases in the expression of NFATc and NFATp
mRNA. A, CD4+CD8+
thymocytes were stimulated with IM/PMA for 20 h and further
cultured for 24 h in the absence of drugs (44 h in total). An
aliquot of the cells was recovered at the indicated time, and the
surface expression of CD69 was assessed. B, thymocytes from
normal BALB/c mice were stained with an anti-CD69 mAb and sorted to
obtain CD69+ and CD69 subsets. C
and D, expression levels of each NFAT member mRNA in
CD69+ and CD69 subsets were assessed by
semi-quantitative RT-PCR. Relative expression levels of NFAT mRNA
were calculated as described in Fig. 7. A representative result of
three experiments is shown.
|
|
 |
DISCUSSION |
Several research groups including ours have previously shown that
the immunosuppressant FK506 or cyclosporine A inhibits positive selection in fetal thymus organ cultures or reaggregated cultures (9-11). The two major requirements for thymocyte-positive selection are to rescue CD4+CD8+ thymocytes from
apoptosis and to induce differentiation of the cells to the CD4 or CD8
SP stage. FK506 inhibits the IM/PMA-induced differentiation of
CD4+CD8+ thymocytes in suspension cultures
(Fig. 2) and annuls the anti-apoptotic effect of IM/PMA (10, 25),
suggesting that both the inhibition of apoptosis and the induction of
differentiation are dependent on FK506-sensitive reactions. Rapamycin,
another immunosuppressant that binds to FKBP12 without affecting CN
activity, fails to inhibit differentiation (data not shown) or to annul
the anti-apoptotic effect (10). The CD4+CD8+
lymphoma RLm6 becomes CD4 SP by incubation with the same combination of
IM/PMA, and differentiation or transition of the cells is also inhibited by FK506 (38). Furthermore, RLm6 transfected with an
expression vector encoding an active form of CN became CD4 SP upon
stimulation with PMA alone (38). These findings collectively suggest
that CN plays a pivotal role in Ca2+ signaling for positive selection.
IM induces a sustained increase in intracellular Ca2+ level
([Ca2+]i), thereby inducing CN activation.
Prolonged elevation of [Ca2+]i levels and CN
activation in T cells are dependent on the capacitative calcium entry,
a process that couples the release of calcium from intracellular stores
with the influx of extracellular Ca2+ through specialized
calcium channels (45, 46). Upon stimulation through the TCR/CD3
complex, immature thymocytes show a much lower increase in
[Ca2+]i compared with mature T cells (47, 48).
However, co-stimulation through some of the accessory molecules has
been shown to enhance and/or prolong the TCR/CD3-mediated increase in
[Ca2+]i in immature thymocytes (10, 49, 50) and
to potentiate the calcineurin-dependent anti-apoptotic
effect (10). Although IM directly releases Ca2+ from the
intracellular stores and brings extracellular Ca2+ into the
cells (51, 52), the dose and duration of IM treatment are crucial for
the survival and differentiation of CD4+CD8+
thymocytes (Figs. 1 and 2) (21, 22), indicating that IM effectively mimics the calcium signal induced by TCR- and accessory
molecule-mediated stimulation. Indeed, in accord with the
IM/PMA-induced thymocyte differentiation, it has been reported that
stimulation of isolated CD4+CD8+ thymocytes by
cross-linking of TCR and some of the accessory molecules overnight,
followed by culturing without stimulation, results in the
differentiation and commitment of the cells to the CD4-T cell lineage
(53).
To maintain the NFAT activated and localized in the nucleus, a
sustained increase in [Ca2+]i is required (54,
55). The activation and nuclear localization of NFAT precisely follows
the activation of CN in T cells and can even last for many hours
depending on increased levels of [Ca2+]i
(56-58). It has been suggested that positive selection involves
sustained interactions with the thymic microenvironment and that
CN-mediated signaling is required at least until
CD4+CD8+ cells become CD69+ (11).
The active CN dephosphorylates NFATs that reside in the cytoplasm and
induces their translocation to the nucleus. NFATx is preferentially
expressed in CD4+CD8+ thymocytes, and mice
lacking NFATx have impaired development of CD4 and CD8 SP thymocytes
and peripheral T cells partly due to increased apoptosis of
CD4+CD8+ thymocytes (16). Thus, NFATx appears
to play an important role in the successful generation of T cells.
However, it has been difficult to induce and detect NFAT DNA binding
activity itself in nuclear extracts of murine
CD4+CD8+ thymocytes (39, 40). By using human
fetal thymocytes, NFATx DNA binding activity could be induced and
detected in CD4+CD8+ thymocytes for the first
time by stimulating the cells with A23187/PMA (29). The nuclear
extraction method and/or the low ionic strength conditions for EMSA
rather than the drug concentrations might be crucial in detecting the
activity. In the present study, by employing a much weaker stimulation
with IM/PMA and the same nuclear extraction method, we could also
induce and detect the DNA binding activity of NFATx in the nucleus of
murine CD4+CD8+ thymocytes (Fig. 5). Transient
stimulation of isolated CD4+CD8+ thymocytes
with this combination of drugs results in differentiation of the cells
to semi-mature CD4 SP and CD4+CD8low T cells
that are committed to the CD4-T cell lineage (21, 22). DNA binding
activities of NFATp and NFATc were also detected in the nucleus of
stimulated murine CD4+CD8+ thymocytes (Fig. 5).
In human fetal CD4+CD8+ thymocytes stimulated
with 0.25 µM A23187 and 5 ng/ml PMA for 3 h, NFATx
was almost the sole contributor to the NFAT DNA binding activity,
although the DNA binding activities of NFATc and NFATp might be
slightly induced (29). This small discrepancy may be partly due to the
differences in stimulation conditions, cell preparation methods, or
species. Especially, it is noteworthy that a marked increase in the DNA
binding activity of NFATc depends on sustained stimulation (15 h) of
the cells without a significant loss of viability (Figs. 3 and 5),
whereas in the previous studies, the cells were stimulated for
relatively short periods.
Both the mRNA expression and DNA binding activity of NFATc
dramatically increased and remained high until the end of the first stimulation in our system (Figs. 5 and 7). On the other hand, the
expression levels of NFATx mRNA decreased during the first stimulation period (Fig. 7), and the DNA binding activity of NFATx protein decreased after the early rise (Fig. 5). Since calcineurin activity appears to be required almost throughout the stimulation period to induce differentiation of the cells to the CD4 T-cell lineage
(Fig. 2), both the early rise of NFATx activity and the late increase
in NFATc activity may contribute to the differentiation of
CD4+CD8+ thymocytes to the semi-mature stage.
Indeed, in the normal thymus, the expression levels of NFATc mRNA
in CD69+ cells were higher than those in CD69
cells, whereas the expression levels of NFATx mRNA in
CD69+ cells were lower than those in CD69
cells (Fig. 8). CD69 is considered to be transiently expressed in the
cells undergoing positive selection or the cells that had been selected
recently in the thymus (43, 44). In chimeric mice lacking NFATc,
reconstitution of thymus is quantitatively impaired (17, 18). Thus, the
deficiency of NFATx and that of NFATc differentially affect T cell
development, suggesting that NFATx and NFATc have distinct roles during
T cell development. Since NFATx binds to the distal NFAT-binding site
in the IL-2 promoter and a NFAT-binding site in the IL-4 promoter with
weaker affinity than NFATc and NFATp (14, 59), the DNA binding
specificity of NFATx may be somehow different from that of the other
members. NFATx may mainly act through unspecified DNA sequences
different from the known NFAT-binding sites (29). However, it is also possible that the two members can replace each other to some extent since the deficiency of either NFATx or NFATc alone does not absolutely prohibit developmental programs (16-18). There is no evidence that NFATp deficiency affects thymic development (19, 20). On the other
hand, NFATc deficiency and NFATp/NFATx deficiency differentially affect
the production of Th1/Th2 cytokines by peripheral T cells (17, 18, 60).
The DNA binding activity of NFATp was detected in our system but was
kept at low levels during the first stimulation period. However, after
the secondary pulse stimulation with a combination of IM/PMA followed
by IL-2 treatment, NFATp became the major NFAT member (Fig. 6 and 7).
The resultant cells were phenotypically and functionally mature and
activated T cells as described previously (22). Thus, the expression
and activation of NFATx, NFATc, and NFATp were sequentially changed
during the T cell development and maturation in vitro. Since
the cells were only exposed to a limited number of stimuli and not
microenvironments in the thymus or peripheral lymphoid organs, the
findings suggest that the changes in NFAT members may be intrinsically
programmed and may reflect alterations in patterns of gene expression
along with T cell development.
In the thymus it is likely that interactions between thymocytes and
stromal cells induce not only an increase in
[Ca2+]i but also other signals including those
that activate protein kinase C and those that suppress the protein
kinase C signaling in thymocytes through TCR and accessory molecules
(61, 62). The net signals may determine the fate of each thymocyte. The
combination of IM and PMA may bypass the complexity of TCR- and
accessory molecule-proximal signals in CD4+CD8+
thymocytes in the same way that combinations of higher concentrations of IM and PMA bypass the early consequence of TCR cross-linking in
mature T cells but mimic its late consequence including gene expression
(37). It is known that TCR cross-linking activates both p21ras
and protein kinase C and that protein kinase C activation with PMA
directly induces p21ras and Raf activation, followed by
activation of the mitogen-activated protein kinase cascade (37).
Recently, Kaye and co-workers (63) indicated that slow accumulation of
active extracellular signal-regulated kinase is critical for
IM/PMA-induced differentiation.
By using a reporter gene with the promoter region of IL-2 gene, it has
been shown that PMA enhances the transcriptional activity of NFAT
depending on p21ras activation and that the enhanced activity
is likely to involve co-operation between NFAT and AP-1 (37). Since
treatment of CD4+CD8+ thymocytes with PMA or IM
alone fails to induce positive selection (21), the expression of genes
essential for positive selection may also depend on the co-operation of
NFAT with other transcription factors such as AP-1 and NF-
B. The
transcriptional regulation of positive selection may involve
LKLF, Notch, IRF-1, and Egr (64), but is as of yet largely unknown. The in vitro
differentiation system used in the present study may also provide a
useful tool for finding the responsible genes.
 |
ACKNOWLEDGEMENTS |
We thank Dr. K.-I. Arai for kind support, Dr.
A. Rao for pGLP3-mNFAT1C, S. Kamijo and co-workers for their help in
producing transgenic mice, Y. Shirota-Someya for her technical
assistance, and A. Nakamura, M. Shiomi, and Y. Kishi for secretarial assistance.
 |
FOOTNOTES |
*
This work was supported in part by grants from the Ministry
of Education, Sports, Science, and Culture of Japan, the Ministry of
Public Welfare of Japan, and the Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Pharmaceutical Safety and Research of Japan.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Integrative
Projects, Mitsubishi Kasei Institute of Life Sciences, 11 Minamiooya, Machida-shi, Tokyo 194-8511, Japan. Tel.: 81-427-24-6397; Fax: 81-427-24-6316; E-mail: iwata@libra.ls.m-kagaku.co.jp.
 |
ABBREVIATIONS |
The abbreviations used are:
SP, single-positive;
[Ca2+]i: intracellular Ca2+ level, CN, calcineurin;
EMSA, electrophoretic mobility shift assay;
IM, ionomycin;
TCR, T cell receptor;
PMA, phorbol 12-myristate 13-acetate;
Ab, antibody;
mAb, monoclonal Ab;
bp, base pair(s);
RT-PCR, reverse
transcription-polymerase chain reaction;
IL, interleukin.
 |
REFERENCES |
| 1.
|
Egerton, M.,
Scollay, R.,
and Shortman, K.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
2579-2582[Abstract/Free Full Text]
|
| 2.
|
Ramsdell, F.,
and Fowlkes, B. J.
(1989)
J. Immunol.
143,
1467-1471[Abstract]
|
| 3.
|
Zuñiga-Pflücker, J. C.,
MacCarthy, S. A.,
Weston, M.,
Longo, D. L.,
Singer, A.,
and Kruisbeek, A. M.
(1989)
J. Exp. Med.
169,
2085-2096[Abstract/Free Full Text]
|
| 4.
|
Fine, J. S.,
and Kruisbeek, A. M.
(1991)
J. Immunol.
147,
2852-2859[Abstract]
|
| 5.
|
Negishi, I.,
Motoyama, N.,
Nakayama, K.,
Nakayama, K.,
Senju, S.,
Hatakeyama, S.,
Zhang, Q.,
Chan, A. C.,
and Loh, D. Y.
(1995)
Nature
376,
435-438[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Fischer, K.-D.,
Zmuidzinas, A.,
Gardner, S.,
Barbacid, M.,
Bernstein, A.,
and Guidos, C.
(1995)
Nature
374,
474-477[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Swan, K. A.,
Alberola-Ila, J.,
Gross, J. A.,
Appleby, M. W.,
Forbush, K. A.,
Thomas, J. F.,
and Perlmutter, R. M.
(1995)
EMBO J.
14,
276-285[Medline]
[Order article via Infotrieve]
|
| 8.
|
Alberola-Ila, J.,
Forbush, K. A.,
Seger, R.,
Krebs, E. G.,
and Perlmutter, R. M.
(1995)
Nature
373,
620-623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Wang, C.-R.,
Hashimoto, K.,
Kubo, S.,
Yokochi, T.,
Kubo, M.,
Suzuki, M.,
Suzuki, K.,
Tada, T.,
and Nakayama, T.
(1995)
J. Exp. Med.
181,
927-941[Abstract/Free Full Text]
|
| 10.
|
Zhao, Y.,
and Iwata, M.
(1995)
Int. Immunol.
7,
1387-1396[Abstract/Free Full Text]
|
| 11.
|
Wilkinson, R. W.,
Anderson, G.,
Owen, J. J. T.,
and Jenkinson, E. J.
(1995)
J. Immunol.
155,
5234-5240[Abstract]
|
| 12.
|
McCaffrey, P. G.,
Luo, C.,
Kerppola, T. K.,
Jain, S.,
Badalian, T. M.,
Ho, A. H.,
Burgeon, E. B.,
Lane, W. S.,
Lambert, J. N.,
Curran, T.,
Verdine, G. L.,
Rao, A.,
and Hogan, P. G.
(1993)
Science
262,
750-754[Abstract/Free Full Text]
|
| 13.
|
Northrop, J. P.,
Ho, S. N.,
Chen, L.,
Thomas, D. J.,
Timmerman, L. A.,
Nolan, G. P.,
Admon, A.,
and Crabtree, G. R.
(1994)
Nature
369,
497-502[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Hoey, T.,
Sun, Y.-L.,
Williamson, K.,
and Xu, X.
(1995)
Immunity
2,
461-472[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Masuda, E. S.,
Naito, Y.,
Tokumitsu, H.,
Campbell, D.,
Saito, F.,
Mannum, C.,
Arai, K.-I.,
and Arai, N.
(1995)
Mol. Cell. Biol.
15,
2697-2706[Abstract]
|
| 16.
|
Oukka, M.,
Ho, I.-C.,
de la Brousse, F. C.,
Hoey, T.,
Grusby, M. J.,
and Glimcher, L. H.
(1998)
Immunity
9,
295-304[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Ranger, A. M.,
Hodge, M. R.,
Gravallese, E. M.,
Oukka, M.,
Davidson, L.,
Alt, F. W.,
de la Brousse, F. C.,
Hoey, T.,
Grusby, M.,
and Glimcher, L. H.
(1998)
Immunity
8,
125-134[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Yoshida, H.,
Nishida, H.,
Takimoto, H.,
Marengère, L. E. M.,
Wakham, A. C.,
Bouchard, D.,
Kong, Y.-Y.,
Ohteki, T.,
Shahinian, A.,
Bachmann, M.,
Ohasgi, P. S.,
Penninger, J. M.,
Crabtree, G. R.,
and Mak, T. W.
(1998)
Immunity
8,
115-124[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Hodge, M. R.,
Ranger, A. M.,
Charles de la Brousse, F.,
Hoey, T.,
Grusby, M. J.,
and Glimcher, L. H.
(1996)
Immunity
4,
397-405[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Xanthoudakis, S.,
Viola, J. P. B.,
Show, K. T. Y.,
Luo, C.,
Wallace, J. D.,
Bozza, P. T.,
Curran, T.,
and Rao, A.
(1996)
Science
272,
892-895[Abstract]
|
| 21.
|
Ohoka, Y.,
Kuwata, T.,
Tozawa, Y.,
Zhao, Y.,
Mukai, M.,
Motegi, Y.,
Suzuki, R.,
Yokoyama, M.,
and Iwata, M.
(1996)
Int. Immunol.
8,
297-306[Abstract/Free Full Text]
|
| 22.
|
Iwata, M.,
Kuwata, T.,
Mukai, M.,
Tozawa, Y.,
and Yokoyama, M.
(1996)
Eur. J. Immunol.
26,
2081-2086[Medline]
[Order article via Infotrieve]
|
| 23.
|
Ohoka, Y.,
Kuwata, T.,
Asada, A.,
Zhao, Y.,
Mukai, M.,
and Iwata, M.
(1997)
J. Immunol.
158,
5707-5716[Abstract]
|
| 24.
|
Iwata, M.,
Hanaoka, S.,
and Sato, K.
(1991)
Eur. J. Immunol.
21,
643-648[Medline]
[Order article via Infotrieve]
|
| 25.
|
Zhao, Y.,
Tozawa, Y.,
Iseki, R.,
Mukai, M.,
and Iwata, M.
(1995)
J. Immunol.
154,
6346-6354[Abstract]
|
| 26.
|
Iwata, M.,
Ohoka, Y.,
Kuwata, T.,
and Asada, A.
(1996)
Stem Cells
14,
632-641[Abstract]
|
| 27.
|
Shinkai, Y.,
Rathbum, G.,
Lam, K.-D.,
Oltz, E. M.,
Stewart, V.,
Mendelsohn, M.,
Charron, J.,
Datta, M.,
Young, F.,
Stall, A. M.,
and Alt, F. W.
(1992)
Cell
68,
855-867[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Suzuki, H.,
Punt, J. A.,
Granger, L. G.,
and Singer, A.
(1995)
Immunity
2,
413-425[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Amasaki, Y.,
Masuda, E. S.,
Imamura, R.,
Arai, K.,
and Arai, N.
(1998)
J. Immunol.
160,
2324-2333[Abstract/Free Full Text]
|
| 30.
|
Schreiber, E.,
Matthias, P.,
Muller, M. M.,
and Schaffner, W.
(1989)
Nucleic Acids Res.
17,
6419[Free Full Text]
|
| 31.
|
Jie, L.,
Koyano-Nakagawa, N.,
Amasaki, Y.,
Saito-Ohara, F.,
Ikeuchi, T.,
Imai, S.,
Takano, T.,
Arai, N.,
Yokota, T.,
and Arai, K.-I.
(1997)
Mol. Biol. Cell
8,
157-170[Abstract]
|
| 32.
|
Pan, S.,
Koyano, N. N.,
Tsuruta, L.,
Amasaki, Y.,
Yokota, T.,
Mori, S.,
Arai, N.,
and Arai, K.-I.
(1997)
Biochem. Biophys. Res. Commun.
240,
314-323[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Luo, C.,
Burgeon, E.,
Carew, J. A.,
McCaffrey, P. G.,
Badalian, T. M.,
Lane, W. S.,
Hogan, P. G.,
and Rao, A.
(1996)
Mol. Cell. Biol.
16,
3955-3966[Abstract]
|
| 34.
|
Watanabe, M.,
Muramatsu, M.,
Hirai, H.,
Suzuki, T.,
Fujisawa, J.,
Yoshida, M.,
Arai, K.-I.,
and Arai, N.
(1993)
Oncogene
8,
2949-2958[Medline]
[Order article via Infotrieve]
|
| 35.
|
Wong, H.,
Anderson, W. D.,
Cheng, T.,
and Riabowol, K.
(1994)
Anal. Biochem.
223,
251-258[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Liu, J.,
Farmer, J. D., Jr.,
Lane, W. S.,
Friedman, J.,
Weissman, I.,
and Schreiber, S. L.
(1991)
Cell
66,
807-815[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Cantrell, D.
(1996)
Annu. Rev. Immunol.
14,
259-274[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Kuwata, T.,
Asada, A,.,
Ohoka, Y.,
Mukai, M.,
Miyaike, M.,
and Iwata, M.
(1998)
Bichem. Biophys. Res. Commun.
247,
242-248[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Rincón, M.,
and Flavell, R. A.
(1996)
Cell Biol.
16,
1074-1084
|
| 40.
|
Simon, A. K.,
Auphan, N.,
and Schmitt-verhulst, A.-M.
(1996)
Int. Immunol.
8,
1421-1428[Abstract/Free Full Text]
|
| 41.
|
Chen, F.,
Chen, D.,
and Rosenberg, E. V.
(1999)
Int. Immunol.
11,
677-688[Abstract/Free Full Text]
|
| 42.
|
Gómez, J.,
Martínez-A, C.,
González, A.,
García, A.,
and Rebollo, A.
(1998)
Oncogene
17,
1235-1243[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Swat, W.,
Dessing, M.,
von Boehmer, H.,
and Kisielow, P.
(1993)
Eur. J. Immunol.
23,
739-746[Medline]
[Order article via Infotrieve]
|
| 44.
|
Yamashita, I,
Nagata, T.,
Tada, T.,
and Nakayama, T.
(1993)
Int. Immunol.
5,
1139-1150[Abstract/Free Full Text]
|
| 45.
|
Putney, J. W. J.
(1990)
Cell Calcium
11,
611-624[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Clapham, D. E.
(1995)
Cell
80,
259-268[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Havran, W. L.,
Poenie, M.,
Kimura, J.,
Tsien, R.,
Weiss, A.,
and Allison, J. P.
(1987)
Nature
330,
170-173[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Finkel, T. H.,
McDuffie, M.,
Kappler, J. W.,
Marrack, P.,
and Cambier, J. C.
(1987)
Nature
330,
179-181[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Deusch, K.,
Daley, J. F.,
Levine, H.,
Languet, A. J., III,
Anderson, P.,
Schlossman, S. F.,
and Blue, M. L.
(1990)
J. Immunol.
144,
2851-2858[Abstract]
|
| 50.
|
Gilliland, L. K.,
Teh, H. S.,
Uckun, F. M.,
Norris, N. A.,
Teh, S. J.,
Schieven, G. L.,
and Ledbetter, J. A.
(1991)
J. Immunol.
146,
1759-1765[Abstract]
|
| 51.
|
Mason, M. J.,
and Grinstein, G.
(1993)
Biochem. J.
296,
33-39
|
| 52.
|
Morgan, A. J.,
and Jacob, R.
(1994)
Biochem. J.
300,
665-672
|
| 53.
|
Cibotti, R.,
Punt, J. A.,
Dash, K. S.,
Sharrow, S. O.,
and Singer, A.
(1997)
Immunity
6,
245-255[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Timmerman, L. A.,
Clipstone, N. A.,
Ho, S. N.,
Northrop, J. P.,
and Crabtree, G. R.
(1996)
Nature
383,
837-840[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Dolmetsch, R. E.,
Lewis, R. S.,
Goodnow, C. C.,
and Healy, J. I.
(1997)
Nature
386,
855-858[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Ruff, V. A.,
and Leach, K. L.
(1995)
J. Biol. Chem.
270,
22602-22607[Abstract/Free Full Text]
|
| 57.
|
Loh, C.,
Shaw, K. T.-Y.,
Carew, J.,
Viola, J. P. B.,
Luo, C.,
Perrino, B. A.,
and Rao, A.
(1996)
J. Biol. Chem.
271,
10884-10891[Abstract/Free Full Text]
|
| 58.
|
Shibasaki, F.,
Price, E. R.,
Milan, D.,
and McKeon, F.
(1996)
Nature
382,
370-373[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Ho, S. N.,
Thomas, D. J.,
Timmerman, L. A.,
Li, X.,
Franvke, U.,
and Crabtree, G. R.
(1995)
J. Biol. Chem.
270,
19898-19907[Abstract/Free Full Text]
|
| 60.
|
Ranger, A. M.,
Oukka, M.,
Rengarajan, J.,
and Glimcher, L. H.
(1998)
Immunity
9,
627-635[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Porritt, H. E.,
Anderson, K. L.,
Suniara, R. K.,
Jenkinson, E. J.,
and Owen, J. J. T.
(1998)
|